Diabetologia

Managing high blood sugar in type 2 diabetes: 2018 guidelines from major diabetes associations

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

New recommendations emphasize lifestyle management and support for type 2 diabetes management.

  • A systematic review of literature since 2014 informed updates to diabetes management recommendations.
  • Weight loss strategies, including lifestyle changes, medication, and surgical interventions, are recommended for individuals with obesity.
  • For patients with cardiovascular disease, SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefits are advised.
  • SGLT2 inhibitors are recommended for patients with chronic kidney disease or clinical heart failure alongside atherosclerotic cardiovascular disease.
  • GLP-1 receptor agonists are generally recommended as the first injectable medication for diabetes management.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '18
Guidelines for Managing High Blood Sugar in Type 2 Diabetes, 2018
cited by 2,226 papers
research support, n.i.h., extramural
Dec '22
Use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes patients based on 2019 European and American treatment guidelines
top 5% journal
cited by 32 papers
research support, non-u.s. gov't
Dec '19
Updated 2019 Guidelines for Managing High Blood Sugar in Type 2 Diabetes from the American and European Diabetes Associations
top 1% journal
cited by 983 papers
historical article
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Mar '25
Improving prescriptions of two diabetes medicines for high-risk patients in Veterans Affairs clinics
top 20% journal
cited by 11 papers
journal article
May '25
Glucagon-like peptide-1 drugs vs. sodium/glucose transporter inhibitors for reducing kidney failure and death in type 2 diabetes patients with kidney disease
top 5% journal
cited by 6 papers
comparative study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief